OverviewSuggest Edit

    MDxHealth is a molecular diagnostics company that develops and commercializes advanced tests for cancer assessment and the personalized treatment of patients. Applying our patented DNA methylation platform and biomarkers, we help address a large and growing unmet medical need for better cancer diagnosis and treatment information. MDxHealth is a publicly-listed company trading on the NYSE Euronext (NYSE as in New York Stock Exchange) markets of Brussels and Amsterdam under the ticker symbol "MDXH". MDxHealth (formerly OncoMethylome Sciences) was established in 2003 and is headquartered in Belgium. Its US headquarters is located in Durham, NC. MDxHealth develops molecular diagnostic products on its own or in partnership with pharmaceutical companies. Some of its products are already commercialized and the company has a broad pipeline of other products for major cancer indications.
    HQHerstal, BE
    Employee Ratings3.1

    Latest Updates

    Employees (est.) (Dec 2018)187(-19%)
    Job Openings7

    Key People/Management at MDxHealth

    Koen Hoffman

    Koen Hoffman

    Michael K. McGarrity

    Michael K. McGarrity

    Chief Executive Officer
    Joseph Sollee

    Joseph Sollee

    Executive Vice President of Corporate Development and General Counsel
    Walter Narajowski

    Walter Narajowski

    John Bellano

    John Bellano

    Chief Commercial Officer
    Ron Kalfus

    Ron Kalfus

    Chief Financial Officer
    Show more

    MDxHealth Office Locations

    MDxHealth has offices in Herstal, Irvine and Nijmegen
    Herstal, BE (HQ)
    31 Rue d'Abhooz
    Nijmegen, NL
    Transistorweg 7
    Irvine, US
    15279 Alton Pkwy #100
    Show all (3)

    MDxHealth Online and Social Media Presence

    Embed Graph

    MDxHealth News and Updates

    MDxHealth Reports Financial Year 2019 Results and Provides Outlook for 2020

    Conference call with Q&A today at 09:00 CET / 08:00 GMT, details provided below

    MDxHealth Provides Q3-2019 Business Update

    IRVINE, CA, and HERSTAL, BELGIUM – November 11, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today provided a business update for the three and nine months ended September 30, 2019. 

    MDxHealth Successfully Completes a EUR 9.0 Million (USD 9.8 Million)(1) Capital Increase

    Press release Regulated information – Inside information27 September 2019, 6:00 a.m. CEST

    MDxHealth Reports Half Year 2019 Financial Results and Strategic Update

    Conference call with Q&A today at 11:00 CEST / 10:00 BST, details provided below

    MDxHealth (R): MDxHealth Announces Favorable Draft Medicare Coverage for the SelectMDx Test

    IRVINE, CA – August 26, 2019 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today announced that Palmetto GBA, a Medicare Administrative Contractor (MAC) that assesses molecular diagnostic technologies under its MolDx program, has issued a draft loca…

    MDxHealth: MDxHealth Notice of Interim Results 2019

    Show more

    MDxHealth Frequently Asked Questions

    • When was MDxHealth founded?

      MDxHealth was founded in 2004.

    • Who are MDxHealth key executives?

      MDxHealth's key executives are Koen Hoffman, Michael K. McGarrity and Joseph Sollee.

    • How many employees does MDxHealth have?

      MDxHealth has 187 employees.

    • Who are MDxHealth competitors?

      Competitors of MDxHealth include 4TEEN4 Pharmaceuticals, Dadi and Athelas.

    • Where is MDxHealth headquarters?

      MDxHealth headquarters is located at 31 Rue d'Abhooz, Herstal.

    • Where are MDxHealth offices?

      MDxHealth has offices in Herstal, Irvine and Nijmegen.

    • How many offices does MDxHealth have?

      MDxHealth has 3 offices.